OBJECTIVE: In mast cell (MC) neoplasms, clinical problems requiring therapy include local aggressive and sometimes devastating growth of MCs and mediator-related symptoms. A key mediator of MCs responsible for clinical symptoms is histamine. Therefore, use of histamine receptor (HR) antagonists is an established approach to block histamine effects in these patients. MATERIALS AND METHODS: We screened for additional beneficial effects of HR antagonists and asked whether any of these agents would also exert growth-inhibitory effects on primary neoplastic MCs, the human MC line HMC-1, and on two canine MC lines, C2 and NI-1. RESULTS: We found that the HR1 antagonists terfenadine and loratadine suppress spontaneous growth of HMC-1, C2, and NI-1 cells, as well as growth of primary neoplastic MCs in all donors tested (human patients, n = 5; canine patients, n = 8). The effects of both drugs were found to be dose-dependent (IC(50): terfenadine, 1-20 μM; loratadine, 10-50 μM). Both agents also produced apoptosis in neoplastic MCs and augmented apoptosis-inducing effects of two KIT-targeting drugs, PKC412 and dasatinib. The other HR1 antagonists (fexofenadine, diphenhydramine) and HR2 antagonists (famotidine, cimetidine, ranitidine) tested did not exert substantial growth-inhibitory effects on neoplastic MCs. None of the histamine receptor blockers were found to modulate cell-cycle progression in neoplastic MCs. CONCLUSIONS: The HR1 antagonists terfenadine and loratadine, in addition to their antimediator activity, exert in vitro growth-inhibitory effects on neoplastic MCs. Whether these drugs (terfenadine) alone, or in combination with KIT inhibitors, can also affect in vivo neoplastic MC growth remains to be determined.
OBJECTIVE: In mast cell (MC) neoplasms, clinical problems requiring therapy include local aggressive and sometimes devastating growth of MCs and mediator-related symptoms. A key mediator of MCs responsible for clinical symptoms is histamine. Therefore, use of histamine receptor (HR) antagonists is an established approach to block histamine effects in these patients. MATERIALS AND METHODS: We screened for additional beneficial effects of HR antagonists and asked whether any of these agents would also exert growth-inhibitory effects on primary neoplastic MCs, the human MC line HMC-1, and on two canine MC lines, C2 and NI-1. RESULTS: We found that the HR1 antagonists terfenadine and loratadine suppress spontaneous growth of HMC-1, C2, and NI-1 cells, as well as growth of primary neoplastic MCs in all donors tested (humanpatients, n = 5; caninepatients, n = 8). The effects of both drugs were found to be dose-dependent (IC(50): terfenadine, 1-20 μM; loratadine, 10-50 μM). Both agents also produced apoptosis in neoplastic MCs and augmented apoptosis-inducing effects of two KIT-targeting drugs, PKC412 and dasatinib. The other HR1 antagonists (fexofenadine, diphenhydramine) and HR2 antagonists (famotidine, cimetidine, ranitidine) tested did not exert substantial growth-inhibitory effects on neoplastic MCs. None of the histamine receptor blockers were found to modulate cell-cycle progression in neoplastic MCs. CONCLUSIONS: The HR1 antagonists terfenadine and loratadine, in addition to their antimediator activity, exert in vitro growth-inhibitory effects on neoplastic MCs. Whether these drugs (terfenadine) alone, or in combination with KIT inhibitors, can also affect in vivo neoplastic MC growth remains to be determined.
Authors: Laura Rebuzzi; Michael Willmann; Karoline Sonneck; Karoline V Gleixner; Stefan Florian; Rudin Kondo; Matthias Mayerhofer; Anja Vales; Alexander Gruze; Winfried F Pickl; Johann G Thalhammer; Peter Valent Journal: Vet Immunol Immunopathol Date: 2006-11-17 Impact factor: 2.046
Authors: Z Radvány; Z Darvas; K Kerekes; J Prechl; C Szalai; E Pállinger; L Valéria; V L Varga; M Sandor; A Erdei; A Falus Journal: Semin Cancer Biol Date: 2000-02 Impact factor: 15.707
Authors: R Fritsche-Polanz; J H Jordan; A Feix; W R Sperr; G Sunder-Plassmann; P Valent; M Födinger Journal: Br J Haematol Date: 2001-05 Impact factor: 6.998
Authors: Celalettin Ustun; Christopher L Corless; Natasha Savage; Warren Fiskus; Elizabeth Manaloor; Michael C Heinrich; Grant Lewis; Preetha Ramalingam; Ilana Kepten; Anand Jillella; Kapil Bhalla Journal: Leuk Res Date: 2008-11-04 Impact factor: 3.156
Authors: B J Longley; L Tyrrell; S Z Lu; Y S Ma; K Langley; T G Ding; T Duffy; P Jacobs; L H Tang; I Modlin Journal: Nat Genet Date: 1996-03 Impact factor: 38.330
Authors: Emir Hadzijusufovic; Barbara Peter; Laura Rebuzzi; Christian Baumgartner; Karoline V Gleixner; Alexander Gruze; Tuddow Thaiwong; Winfried F Pickl; Vilma Yuzbasiyan-Gurkan; Michael Willmann; Peter Valent Journal: Vet Immunol Immunopathol Date: 2009-05-18 Impact factor: 2.046
Authors: M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti Journal: Osteoporos Int Date: 2016-02-18 Impact factor: 4.507
Authors: Zhi Yuan Kok; Leigh A Stoddart; Sarah J Mistry; Tamara A M Mocking; Henry F Vischer; Rob Leurs; Stephen J Hill; Shailesh N Mistry; Barrie Kellam Journal: J Med Chem Date: 2022-06-03 Impact factor: 8.039
Authors: Jesus Rafael Rodriguez Amado; Ariadna Lafourcade Prada; Jonatas Lobato Duarte; Hady Keita; Heitor Rivero da Silva; Adriana Maciel Ferreira; Edgar Hernandez Sosa; Jose Carlos Tavares Carvalho Journal: Saudi Pharm J Date: 2017-07-19 Impact factor: 4.330